Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12268713-B2
Publication Date
2025-04-08
Expiration Date
Abstract
In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 2 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.
Core Innovation
The invention relates to a composition comprising a cross-linkable protein having at least one RGD (Arg-Gly-Asp) motif and a non-toxic cross-linker that forms a cross-linked porous scaffold. The scaffold is described as a closed cell foam having a Young’s modulus between 0.1 KPa and 11 KPa, and the non-toxic cross-linker is essentially eluted from the cross-linked porous scaffold.
The cross-linkable protein is present in the composition in a range of 0.5 wt % to 25 wt % based on a total weight of the composition, and the non-toxic cross-linker is present in the composition in a range of 0.0001 wt % to 2 wt % based on a total weight of the composition. The composition further includes a liquid in which the cross-linkable protein and the non-toxic cross-linker are mixed.
The document describes applications in tissue defect treatment and tissue engineering contexts, including cell infiltration/proliferation, osteogenesis, sealing/adhesion, and reduced inflammation. The problem described is the need for cross-linked porous tissue-repair scaffolds that provide tissue adherence/sealing and support biological responses while using a non-toxic cross-linker that is essentially eluted from the formed scaffold.
Claims Coverage
Two independent claims are identified. Across them, the inventive focus includes an RGD-motif cross-linkable protein, defined wt% ranges for the protein and non-toxic cross-linker, a cross-linked porous scaffold that is a closed cell foam, a specified Young’s modulus in one claim, and a non-toxic cross-linker that is essentially eluted from the scaffold.
Cross-linkable protein with RGD motif
A composition comprising a cross-linkable protein comprising at least one RGD (Arg-Gly-Asp) motif, wherein the cross-linkable protein is present in the composition in a range of 0.5 wt % to 25 wt % based on a total weight of the composition.
Cross-linked porous scaffold as closed cell foam
A composition comprising a cross-linked porous scaffold, wherein the cross-linked porous scaffold comprises a closed cell foam having a Young’s modulus between 0.1 KPa-11 KPa.
Non-toxic cross-linker essentially eluted from the scaffold
A composition wherein a non-toxic cross-linker is essentially eluted from the cross-linked porous scaffold.
Mixing cross-linkable protein, non-toxic cross-linker, and liquid to form the scaffold
A composition formed by mixing a cross-linkable protein comprising at least one RGD (Arg-Gly-Asp) motif (0.5 wt % to 25 wt %), at least one non-toxic cross-linker (0.0001 wt % to 2 wt %) and a liquid, wherein the composition comprises a cross-linked porous scaffold and the non-toxic cross-linker is essentially eluted from the cross-linked porous scaffold, wherein the cross-linked porous scaffold comprises a closed cell foam.
The independent claims collectively cover an RGD-motif cross-linkable protein composition that forms a cross-linked porous closed cell foam scaffold with a defined foam modulus in one claim and uses a non-toxic cross-linker that is essentially eluted from the scaffold; one claim further specifies mixing with a liquid and the stated wt% ranges.
Stated Advantages
Provides tissue adherence/sealing and supports biological responses.
Supports cell infiltration/proliferation, osteogenesis, sealing/adhesion, and reduced inflammation.
Uses a non-toxic cross-linker that is essentially eluted from the formed scaffold.
Documented Applications
Wounds.
Bone defects.
Incontinence (including sphincter/urinary/fecal incontinence).
Emphysema/lung volume reduction.
Sealing/adhesion.
Tissue engineering site use.
Interested in licensing this patent?